- Open Access
RNA binding proteins co-localize with small tau inclusions in tauopathy
© The Author(s). 2018
- Received: 17 July 2018
- Accepted: 19 July 2018
- Published: 1 August 2018
The development of insoluble, intracellular neurofibrillary tangles composed of the microtubule-associated protein tau is a defining feature of tauopathies, including Alzheimer’s disease (AD). Accumulating evidence suggests that tau pathology co-localizes with RNA binding proteins (RBPs) that are known markers for stress granules (SGs). Here we used proteomics to determine how the network of tau binding proteins changes with disease in the rTg4510 mouse, and then followed up with immunohistochemistry to identify RNA binding proteins that co-localize with tau pathology. The tau interactome networks revealed striking disease-related changes in interactions between tau and a multiple RBPs, and biochemical fractionation studies demonstrated that many of these proteins including hnRNPA0, EWSR1, PABP and RPL7 form insoluble aggregates as tau pathology develops. Immunohistochemical analysis of mouse and human brain tissues suggest a model of evolving pathological interaction, in which RBPs co-localize with pathological phospho-tau but occur adjacent to larger pathological tau inclusions. We suggest a model in which tau initially interacts with RBPs in small complexes, but evolves into isolated aggregated inclusions as tau pathology matures.
- Alzheimer’s disease
- Neurofibrillary tangle
- Mass spectrometry
- Protein interactome
- Protein aggregation
RNA binding proteins (RBPs) have emerged as major factors in a number of neurodegenerative disorders, including tauopathies [31, 32]. RBPs represent a large class of proteins responsible for RNA metabolism, regulating key events including mRNA maturation, trafficking, and eventual translation. Importantly, many RBPs have been shown to have strong genetic links to neurodegenerative disease; for example, mutations in TDP-43, FUS, hnRNPA1, and ATXN2 have all been shown to cause amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD) and/or spinocerebellar ataxia . Other RBPs have also been implicated in AD, Huntington’s disease, and Creutzfeldt-Jakob disease .
Following these initial discoveries, evidence now suggests that transient aggregation mediated by low-complexity domains within RBPs is crucial for the involvement of these proteins in disease. RBPs typically contain a “prion-like”, low complexity glycine-rich domain in their sequences, which regulate their self-aggregation [21, 35]. This regulated aggregation is important for RBP function, as many RBPs regulate the formation of a variety of ribonucleoprotein (RNP) granules. Such granules, which include stress granules (SGs) and P-bodies, are responsible for the transient recruitment and aggregation of mRNA transcripts for varying purposes [29, 32]. SGs recruit mRNA into granules for storage and protection following translational stress, while P-bodies recruit mRNA for eventual degradation [29, 32]. Many disease-linked RBPs are proteins involved in the formation and maintenance of SGs.
In particular, recent findings have shown that T-cell intracellular antigen 1 (TIA1) and other RBPs interact with hyper-phosphorylated tau and accumulate in tandem with tau pathology in diseases such as Alzheimer’s disease (AD) and frontotemporal dementia (FTD) [37, 38]. RBPs also regulate splicing of MAPT exon 10, which provides an additional mechanism for control of tau aggregation by determining whether the tau transcript codes for 3 or 4 microtubule repeats [9, 18, 40]. The aggregation of tau is a major pathological hallmark of these diseases, where the microtubule associated protein tau becomes hyperphosphorylated, and mislocalizes in the soma . Once in the soma, tau begins to aggregate, eventually forming large neurofibrillary tangles and resulting in neurodegeneration. Recently, our lab demonstrated that tau interacts with TIA1 in SGs, which increases in sarkosyl insoluble aggregates. The association of tau with TIA1 and SGs also was shown to promote tau-mediated degeneration of primary hippocampal neurons . This phenotype can be rescued by TIA1 knockdown in primary neurons . We proceeded to show that TIA1 reduction (haploinsufficiency) is also protective in vivo, reducing neurodegeneration, rescuing cognition and increasing survival in the PS19 mouse model of tauopathy . These results point to an essential role for TIA1 and SG biology in the pathophysiology of tauopathy.
We now present an enhanced view of the interaction of RBPs in the pathophysiology of tauopathy. We have used a proteomic approach to identify multiple RBPs that have significantly altered associations with tau as pathology develops in the rTg4510 mouse model of tauopathy including multiple splicing factors. The rTg4510 mouse model of tauopathy inducibly expresses P301L 4R0N tau under control of a tetracycline promoter, and when aged in the absence of doxycycline develop pathology by 4–5 months . We also present optimized immunohistochemical methods for detecting RBPs in pathological tissues. We combine the optimized immunohistochemical methods with biochemical methods to validate the proteomic findings. We identify specific RBPs that associate with pathological phospho-tau early in disease and become increasingly insoluble as disease progresses. Together our results provide important evidence indicating that RNA binding protein pathologies are a major feature of tauopathy.
TIA1 colocalizes with phosphorylated tau in tauopathy
Recent work from our laboratory demonstrates that TIA1 and other SG markers colocalize with pathological tau in Tg4510 and PS19 mouse brains as well as human post-mortem AD and FTDP-17 brain samples [1, 37, 38]. Immunohistochemical identification of TIA1 inclusions in pathological samples has proven to be particularly difficult, with some observing TIA1 inclusions, and others unable to observe inclusions [8, 11, 15]. While this could represent differences in the types of cases examined, we have also observed TIA1 reactivity to be highly sensitive to methodological conditions.
To improve reproducibility among laboratories, we set out to define optimal conditions for TIA1 immunohistochemistry. We began by determining optimal conditions for fixation of mouse tissue. rTg4510 tissues were drop-fixed in 4% buffered paraformaldehyde for 24 or 48 h, then transferred to 30% sucrose, incubated at 4 °C for 48 h, sectioned and subjected to immunohistochemistry. Shorter fixation times produced much stronger reactivity for both TIA1 and NeuN, which is also a RNA binding protein (Additional file 1: Figure S4). The 24 h fixation protocol was used for all subsequent experiments using animal tissues. We also optimized conditions to reduce background. Our previous studies used Sudan black to quench background fluorescence, however such quenching also has the drawback of reducing antibody signals [23, 38]. Photobleaching proved to provide much more effective quenching of autofluorescence without significant loss of antibody reactivity (Additional file 1: Figure S5). Application of shorter fixation times and photobleaching significantly improved the sensitivity for detecting RBPs in tissue samples.
We proceeded to characterize how the co-localization of TIA1 and tau varied with the type of tau pathology. Analysis of patterns of co-localization in 6 month-old rTg4510 brain tissue demonstrated a distinct correlation of TIA1 co-localization with the size of CP13-positive tau inclusions (Fig. 1e, f). Abundant co-localization was observed with small CP13 reactive puncta, while little co-localization was observed with large fibrillar CP13 positive tau inclusions (Fig. 1e). Previous results from our laboratory indicate that TIA1 selectively interacts with oligomeric tau . To test whether the small TIA1 reactive inclusions contained tau oligomers, we probed the tissues with the anti-tau oligomer antibody TOC1 . Strong co-localization was observed between anti-TIA1 and the TOC1 tau oligomer specific antibodies (Fig. 1f, R = − 0.1617, p = 0.0404). From this we conclude that TIA1 preferentially associates with small tau inclusions containing oligomeric tau.
Other RNA binding proteins change in their association to tau in tauopathy
Comparing the tau networks from the induced and un-induced rTg4510 mice revealed striking changes. Multiple proteins showed decreased association with tau in the 2.5 m induced rTg4510 mice. Proteins linked to RNA metabolism comprised 3 of the top 6 GO annotations categories of decreased proteins (Fig. 2a, bottom panel). Interaction of tau with some of these proteins, including HNRNPA0, HNRNPK, eIF4a, and RPL11, was validated by immunoprecipitating tau from 6 month old PS19 P301S tau mouse brains; these mice overexpress mutant P301S tau at 5 times endogenous levels (Additional file 1: Figure S2). Confirmation is also provided by comparison to our prior study showing the requirement of tau for the presence of many proteins in the TIA1 interactome network . These changes corresponded to large-scale changes in the interaction of tau with these particular groups of proteins. For instance, 65% of proteins in the RBP group showed decreased association with disease; in contrast, only 16% of proteins in the synaptic and vesicular protein group showed decreased association with disease (Fig. 2a).
The groups of proteins whose interaction with tau increased with disease were equally striking. Heat shock proteins/chaperones and phospho-proteins were 2 of the 3 groups of proteins upregulated in the 2.5 m induced rTg4510 mouse cortex (Fig. 2a, top panel), with 37% of heat shock or chaperone proteins showing increased association with tau with disease (Fig. 2a). This upregulation is consistent with the stress associated with pre-tangle stage that predominates in the 2.5 m rTg4510 mouse . Interestingly, the third group of proteins whose association with tau increased in the 2.5 m mice was nucleotide binding proteins; these include RBPs such as EWSR1, TAF15 and HNRNPA0, which we previously reported to co-localize with tau pathology in the rTg4510 model of tauopathy  (Fig. 2a, b). In addition, aggregation-enhancing mutations in EWSR1 and TAF15 are associated with ALS, suggesting that changes in the biology of these proteins are sufficient to drive neurodegenerative disease [6, 7]. Taken together, these results highlight that complexes containing tau and RBPs are a major feature of the pathophysiology of tauopathy.
RNA binding proteins become insoluble in tauopathy
RNA binding proteins colocalize with phospho-tau but not mature neurofibrillary tangles in tauopathy
Characterization of the tau interactome in the rTg4510 mouse model of tauopathy reveals striking disease-related changes in interactions between tau and multiple RBPs. About 65% of proteins in the RBP group show decreased tau association with disease. A smaller number of RBPs increase the association of tau with disease, including EWSR1, TAF15 and hnRNPA0, each of which have been linked to ALS (e.g., EWSR1 or TAF15) or have related family members linked to ALS (hnRNPA0 shares homology with hnRNPA2B1). Formation of aggregates was evident biochemically and by immuhistochemisty which is consistent with prior studies showing multiple U1 spliceosome components that accumulate in the sarkosyl-insoluble fraction of AD tissues .
Imaging studies suggest that the pattern of co-localization varied depending on the type of RBP, and the size of the inclusion. For the RBPs examined in this manuscript, TIA1 showed the strongest co-localization with tau pathology. Co-localization for TIA1 with tau could be observed for phospho-tau (CP12, p-S202) and oligomeric tau (TOC1). Other RBPs, including hnRNPA0, DDX6, eIF2α and (to a lesser extent) PABP also co-localized with phospho-tau pathology. Direct co-localization was observed with small tau puncta, but for large tau inclusions these RBPs tended to accumulate immediately adjacent to the inclusion. The observation of RBP inclusions adjacent to tau tangles has also been observed for small nuclear ribonuclear proteins, such as U2AF2 [12, 13]. The differential localization of RBP inclusion with tau aggregate size suggests a model in which these proteins initially co-localize with tau but become excluded as the tau aggregates consolidate into mature neurofibrillary tangles. This work adds key information to our prior data indicating that phospho-tau (specifically, tau phosphorylated at the classic proline directed serine/threonine sites associated with pathology) promotes SG formation .
This model is further supported by accumulating evidence pointing to a persistent translational stress response as a key pathway leading to the accumulation of SGs. Chronic disease could produce a chronic stress, which leads to persistence of SGs. The high concentration of RBPs in SGs (100–400-fold higher than dispersed RBP levels) creates conditions that also promote aggregation of RBPs into insoluble amyloids, which over time accumulate [16, 24, 31]. Support for the persistent SG hypothesis comes from protection experiments in cell culture and in transgenic models. Bonini and colleagues demonstrated that chemical inhibition of the SG pathway rescues the ALS phenotype in drosophila . Ataxin-2 deletion, which also inhibits the SG/translational stress response pathway, also delayed disease progression in a mouse model of ALS . The relevance of the SG pathway to tauopathy was recently demonstrated by our observation that TIA1 reduction protects against disease progression in a mouse model of tauopathy . Studies using primary neurons support these results by demonstrating that both RNAi knockdown of TIA1 and chemical inhibition of the SG pathway are able to prevent tau-mediated toxicity . Thus, multiple independent lines of evidence demonstrate that RBPs, SGs and the translational stress response contribute to the pathophysiology of tauopathy and other neurodegenerative diseases.
The putative role for tau in regulating the RNA metabolism is supported by proteomic studies of tau interactomes from multiple different groups, which also identify similar classes of proteins that associate with tau. Immunoprecipitation and mass spectrometry of tau (both WT and P301L) binding proteins from SH-SY5Y neuroblastoma cells showed strong overlap of RBPs and ribosomal protein with the proteins identified in our study, including EWSR1, DDX5 & 17, hnRNPK, L, R and U, as well as ribosomal proteins RPL7, 8, 27 and 30 . Proteomic studies of complexes containing tau from the rTg4510 mouse model and human AD tissues also report RNA binding and nucleotide binding proteins in their results, as well as multiple heat shock proteins and chaperones [4, 25]; work from the Abrisambra laboratory also directly demonstrates that tau over-expression inhibits RNA translation [25, 26]. Studies using HeLa cells report multiple RBPs in the tau interactome, including TIA1, hnRNP family members, and many ribosomal subunit proteins, and also demonstrated the presence of aggregated RBPs in the AD brain . A recent study of tau-associated proteins in lymphoblastoid cell lines containing AKAP9 mutations linked to AD show enrichment of RNA binding and spliceosomal proteins in the tau proteome . These proteins again include EWSR1, TAF15, DDX family members, and RPL family members, which parallels our findings. Finally, our own work previously demonstrated the association of TIA1 with tau by both proteomic analysis as well as immunoprecipitation . These data demonstrate that identification of complexes containing tau and RBPs is a reproducible observation. The nature of the tau species responsible for binding to each RBP remains to be determined, and might differ between tau monomers, oligomers and fibrils; for instance, our recent study suggest that TIA1 exhibits preference for tau oligomers . The studies also provide strong support for an emerging consensus that tau functions in stress to regulate the translation stress response through interaction with RBPs and SGs.
Our current study combines with accumulating prior studies to suggest that tauopathies (including AD) exist in the spectrum of neurodegenerative diseases and myopathies that are associated with dysfunction of RBPs, which already includes ALS and FTD. The current work advances the field by identifying a number of RBPs that can be reliably associated by immunohistochemistry with tau pathology, and providing optimized methods for detecting the association. These advances will facilitate rigor and reproducibility for this emerging field. Finally, the consistent role of RBPs and SGs in the mechanisms of multiple neurodegenerative diseases suggests that dysfunction of RBPs, SGs and translational stress response pathways plays a fundamental role in the pathophysiology of neurodegenerative diseases, and that seemingly disparate diseases might converge on common downstream mechanisms for neurodegeneration.
Animal husbandry and tissue collection
Animal husbandry for the rTg4510, PS19 and TIA1−/− mice was approved and performed as previously described in each indicated reference. For all brain harvesting, mice were anesthetized in an isoflurane chamber and perfused with ice cold PBS. Brains were then harvested and processed according to each subsequent experiment recorded below.
Human brain samples
AD cases used for immunohistochemical studies
Immunohistochemistry and quantification
All mouse (n = 8 rTg4510 and n = 8 wild type C57BL6/J) and human (n = 7 AD cases and n = 8 aged control) tissue was sectioned at 20um on a cryostat and stained as free floating sections using Netwell baskets (VWR Cat#29442–132) in 12 well Falcon plates (Cat#353043). Extracted mouse tissues were drop fixed in15mL 4% PFA for 24 h, transferred to 15 mL 30% sucrose in PBS for 48 h, then sectioned and stored in cryoprotectant (30% ethylene glycol; 30% glycerol; 40% PBS) at − 20 °C. We note that a recent study of stress granule pathology showed excellent labeling of TIA1 and other RBPs in a mouse model of tauopathy using perfusion with cold paraformaldehyde (4%), followed by drop fixation in cold paraformaldehyde for 2 h, transfer to 30% sucrose in PBS for at least 48 h . Human tissues were fixed and stored in periodate-lysine-paraformaldehyde (PLP) until sectioned using a Leica VT1200S vibratome. To quench lipofuscin autofluorescence, sections were photobleached under a 1500 lm white LED bulb for a minimum of 72 h at 4 °C while suspended in PBS with no lid or covering . Note that the photobleaching is time-limited; sections examined were observed to recover lipofuscin autofluorescence after approximately 1 week following the photobleaching. Sections were then washed 3× in PBS for 30 s each wash followed by a 5-min incubation in detergent media (TBS with 0.25% Triton-X). Human tissue, but not mouse tissue, was then incubated in 1%w/v sodium borohydride (NaBH4; Sigma-Aldrich Cat#452882-25G) in PBS for 45 min to quench aldehyde autofluorescence which results from the over-fixation of tissue. All tissue was then incubated for 1 h in citrate based antigen unmasking solution (Vector Cat#H-3300) at 95 °C, with the exception of human TIA1 staining (Fig. 1), which was done using 0.05% citraconic anhydride (Sigma-Aldrich Cat#125318-25G) for 1 h at 95 °C. Tissue was blocked with gentle rotating for 2 h in detergent media with 5% donkey serum (Sigma-Aldrich D9663-10 mL) in PBS. After blocking, tissue was washed once in PBS for 30 s to remove excess detergent, then moved into 24 well plates with 200uL of the appropriate primary antibody dilutions and no basket overnight at 4 °C. To prevent evaporation, the lids of each plate were lined with a damp Kimwipe. Antibody catalog numbers and dilutions are recorded in Additional file 3: Table S2.
Following primary antibody incubation, tissue sections were washed 4× in PBS using baskets in 12 well plates for 5-min each wash. Tissues were then incubated in 200uL of secondary antibody solution containing a 1:500 dilution of the appropriate secondary antibody (Jackson Immunoresearch Alexafluor-488 and 549 secondaries) for 1.5 h in the dark at room temperature. If needed, after 1.5 h 300uL of a 1μg/mL DAPI solution was added to each tissue and incubated in the dark for 5 min at room temperature. Tissues were then washed 4× in PBS for 5 min each and carefully placed on Millenia 2.0 slides (StatLab Medical Products Cat#318) using a histology brush (Fisher Scientific Cat#NC0344756). Excess water was allowed to evaporate for 15 min, then each slide was mounted with 100uL of Prolong Gold Antifade Reagent (Thermo Fisher Cat#P36930) and a 1 mm cover slip.
All imaging was done using a Zeiss LSM 700 confocal microscope at either 40× or 63× magnification with a 1 AU pinhole. Following imaging, images were processed using either Imaris BitPlane software or the Fiji distribution of ImageJ. An Imaris BitPlane surfaces algorithm (Bitplane AG, Zurich, Switzerland) was used to quantify the tangle size vs. TIA1 intensity recorded in Fig. 1. The Coloc2 plugin of Fiji was used to determine colocalization parameters recorded in Fig. 4 following background subtraction with a rolling ball radius of 50. Intensity plots for Figs. 4 and 5 were also measured and generated using ImageJ-Fiji; regions of interest were set across a line using the line tool, and then measured using analyze- > plot profile.
Tau immunoprecipitation for mass spectrometry analysis
2.5 mo rTg4510 and uninduced transgenic mouse brains (n = 4/group) were extracted, slowly frozen by submersion in methanol on dry ice, and homogenized in RIPA lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, pH 6.8) supplemented with protease (Roche Cat#04693159001) and phosphatase inhibitor (Roche Cat#04906837001) cocktails. Tau was immunoprecipitated from 1 mg cortex lysate using 10 μg of the mouse monoclonal Tau13 antibody immobilized on Pierce Direct IP columns according to manufacturer’s instructions (Thermo Scientific, Cat#26148). The Tau13 IP eluates were then separated on a Novex 4–12% Bis-Tris polyacrylamide gel (Life Technologies, Cat#NP0323) and stained with Simply Blue Coomassie G-250 SafeStain (Life Technologies, Cat#LC6060). Whole gel lanes were then excised and shipped to the UMass Mass Spectrometry and Proteomics facility for analysis by LC-MS/MS.
Proteomics, in gel digestion
Gel slices were cut into 1 × 1 mm pieces and placed in 1.5 ml eppendorf tubes with 1 ml of water for 30 min. The water was removed and 50ul of 250 mM ammonium bicarbonate was added. For reduction 20 μl of a 45 mM solution of 1, 4 dithiothreitol (DTT) was added and the samples were incubated at 50 C for 30 min. The samples were cooled to room temperature and then for alkylation 20 μl of a 100 mM iodoacetamide solution was added and allowed to react for 30 min. The gel slices were washed 2 X with 1 ml water aliquots. The water was removed and 1 ml of 50:50 (50 mM Ammonium Bicarbonate: Acetonitrile) was placed in each tube and samples were incubated at room temperature for 1 h. The solution was then removed and 200 ul of acetonitrile was added to each tube at which point the gels slices turned opaque white. The acetonitrile was removed and gel slices were further dried in a Speed Vac. Gel slices were rehydrated in 75 μl of 2 ng/μl trypsin (Sigma) in 0.01% ProteaseMAX Surfactant (Promega): 50 mM Ammonium Bicarbonate. Additional bicarbonate buffer was added to ensure complete submersion of the gel slices. Samples were incubated at 37C for 21 h. The supernatant of each sample was then removed and placed in a separate 1.5 ml eppendorf tube. Gel slices were further dehydrated with 100 ul of 80:20 (Acetonitrile: 1% formic acid). The extract was combined with the supernatants of each sample. The samples were then dried down in a Speed Vac. Samples were dissolved in 25 μl of 5% Acetonitrile in 0.1% trifluroacetic acid prior to injection on LC/MS/MS.
LC/MS/MS on Q Exactive
A 3.0 μl aliquot was directly injected onto a custom packed 2 cm × 100 μm C18 Magic 5 μm particle trap column. Labeled peptides were then eluted and sprayed from a custom packed emitter (75 μm × 25 cm C18 Magic 3 μm particle) with a linear gradient from 95% solvent A (0.1% formic acid in water) to 35% solvent B (0.1% formic acid in Acetonitrile) in 90 min at a flow rate of 300 nanoliters per minute on a Waters Nano Acquity UPLC system. Data dependent acquisitions were performed on a Q Exactive mass spectrometer (Thermo Scientific) according to an experiment where full MS scans from 300 to 1750 m/z were acquired at a resolution of 70,000 followed by 10 MS/MS scans acquired under HCD fragmentation at a resolution of 17,500 with an isolation width of 1.6 Da. Raw data files were processed with Proteome Discoverer (version 1.4) prior to searching with Mascot Server (version 2.5) against the Uniprot database. Search parameters utilized were fully tryptic with 2 missed cleavages, parent mass tolerances of 10 ppm and fragment mass tolerances of 0.05 Da. A fixed modification of carbamidomethyl cysteine and variable modifications of acetyl (protein N-term), pyro glutamic for N-term glutamine, oxidation of methionine were considered. Search results were loaded into the Scaffold Viewer (Proteome Software, Inc.).
Quantitative proteomic analysis was performed using the total ion current (TIC) for proteins identified by LC-MS/MS normalized to the TIC level of TIA1 detected in each sample. Proteins identified in the TIA1−/− samples were considered to be nonspecific binding proteins to the IP antibody and excluded from all subsequent analyses. Gene lists of detected proteins were then uploaded into the Database for Annotation, Visualization and Integrated Discovery (DAVID) resource available via the NIH website.
The proteins identified in the tau binding proteome in WT C57BL/6 J cortex resulted in 6 identified clusters with enrichment FDR < 0.05, and each of the proteins was associated to the cluster(s) based on its membership in the clustered gene sets. A network was created by adding a connection between protein pairs sharing annotation clusters. Edge weights were determined as the number of shared annotation clusters between protein pairs with thicker edges representing stronger functional associations between proteins (the smallest number of clusters shared between any two proteins was 1, and the largest was 8). The resulting network was visualized using the software Gephi 0.8.2 and arranged using the Force Atlas 2 layout algorithm. The network was generated using the python programming language (Python Software Foundation), and the networkx, numpy, and pandas python packages.
CoIP validation of mass spectrometry
Brains from 6 month old PS19 mice expressing P301S tau were extracted and freshly homogenized using 400uL IP lysis buffer (0.025 M Tris; 0.15 M NaCl; 0.001 M EDTA; 1% NP-40, 5% glycerol; pH 7.4) supplemented with protease inhibitor cocktail (Roche Cat#04693159001), phosphatase inhibitor cocktail (Roche Cat#04906837001), and 20 units RNase inhibitor (ThermoFisher Scientific #AM2964). 1 mg of each lysate was pre-cleared with 80uL Protein G Dynabeads, and 50uL of Protein G Dynabeads (Invitrogen #10004D) per lysate were prepared with either 10μg Tau13 according to manufacturer instructions. Lysates and beads were equivalently pre-cleared and prepared with 10μg normal mouse IgG. Pre-cleared lysates were immunoprecipitated with the antibody conjugated beads using gentle rotation overnight at 4 °C; protein was eluted by boiling in Bolt SDS-PAGE sample buffer for 10 min and analyzed using SDS-PAGE. Antibodies used in the western blot analysis are recorded in supplemental Table 2.
Sarkosyl fractionation and immunoblotting
Extracted brain tissue from (n = 3) rTg4510 and (n = 3) uninduced Tg4510 control mice was weighed and placed in a Beckman centrifuge tube, polycarbonate thick wall (Cat#362305). Tissue was homogenized in 4× weight/volume of homogenization buffer (50 mM Tris; 275 mM NaCl; 5 mM KCl; 1 mM PMSF; pH = 8.0 with protease inhibitors, phosphatase inhibitors and PMSF added immediately before use) and ultracentrifuged at 28 k rpm (29,800 g) in a TLA-55 rotor for 20 min at 4 °C using a Beckman Optima-TLX 120,000 ultracentrifuge. The supernatant was removed and stored at − 80 °C as the TBS soluble supernatant (supernatant S1); excess supernatant was then vacuumed off the pellet, and the pellet was suspended in sucrose buffer (10 mM Tris, pH = 7.4; 0.8 M NaCl; 10% sucrose; 1 mM EGTA; 1 mM PMSF). The suspension was ultracentrifuged at 22 k rpm (26,300 g) for 20 min at 4 °C. 450uL of the supernatant was transferred to a new tube with the pellet stored at − 80 °C (pellet P2). This supernatant was incubated with 1% Sarkosyl for 5 min with gentle rotation at room temperature then 1 h at 37 °C. After Sarkosyl incubation the solutions were ultracentrifuged at 55 k rpm (150,000 g) for 1 h at 4 °C. The supernatant was stored at − 80 °C (supernatant S3) and the pellet was resuspended in 60uL TE buffer (10 mM Tris, pH = 8.0, 1 mM EDTA) and also kept at − 80 °C as the P3 pellet.
The Sarkosyl soluble S3 supernatant and insoluble P3 pellet were analyzed for RBP content using SDS-PAGE and immunoblotting. As the protein concentration of all tissues were normalized at the start of fractionation, 20uL of the P3 pellet and 5uL of the S3 supernatant were run on a Bolt 4–12% Bis-Tris Plus polyacrylamide gel (Life Technologies Cat#NW04127BOX) at 120 V for 1 h and 15 min. Proteins were transferred onto nitrocellulose at 12 V for 1 h, and membranes were blocked in Tris-buffered saline (24 g Tris base; 88 g NaCl; 1 L water; pH = 7.6) with 0.1% Tween (TBS-T); with 5% non-fat milk for 2 h. After blocking membranes were incubated with 10 mL of the appropriate primary antibody in TBS-T overnight at 4 °C; primary antibodies and dilutions are recorded in supplementary Table 2. Membranes were washed 4× for 5 min each was in TBS-T, then incubated with the appropriate HRP-conjugated secondary antibody at a 1:15,000 dilution in TBS-T (Jackson Immunoresearch) for 1.5 h. Membranes were again washed 4× for 5 min each in TBS-T then developed using Pierce SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific Cat#34080). Blots were quantified using ImageJ peak analysis.
Human brain tissue was generously provided by the National Institute of Aging Boston University AD Center (P30AG13846). We would like to thank the following funding agencies for their support: BW: NIH (AG050471, NS089544, ES020395, AG056318) BrightFocus Foundation, Alzheimer Association, Cure Alzheimer’s Fund and the Thome Medical Foundation; BM: NS106751. JA: NIH (NS091329, AG028383, MD009205), Alzheimer’s Association NIRG-14-322441, Department of Defense AZ140097.
BFM designed experiments, carried out immunochemical and immunohistochemical experiments, and drafted the manuscript. DJA and LJ designed experiments, carried out immunochemical and immunohistochemical experiments. ALC carried out immunohistochemical experiments. ELdR, CZ and HL performed bio-informatics studies and designed related figures, JL performed mass spectroscopy, WHY and JFA provided tissues and helped to edit the manuscript. BW conceived of the study, participated in the studies coordination, designed experiments, drafted the manuscript. All authors read and approved the final manuscript.
BW is co-founder and Chief Scientific Officer of Aquinnah Phamraceuticals Inc.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Apicco DJ, Ash PEA, Maziuk B, LeBlang C, Medalla M, Al Abdullatif A, Ferragud A, Botelho E, Ballance HI, Dhawan U et al (2018) Reducing the RNA binding protein TIA1 protects against tau-mediated neurodegeneration in vivo. Nat Neurosci 21:72–80. https://doi.org/10.1038/s41593-017-0022-z View ArticlePubMedGoogle Scholar
- Bai B, Hales CM, Chen PC, Gozal Y, Dammer EB, Fritz JJ, Wang X, Xia Q, Duong DM, Street C et al (2013) U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease. Proc Natl Acad Sci U S A 110:16562–16567. https://doi.org/10.1073/pnas.1310249110 View ArticlePubMedPubMed CentralGoogle Scholar
- Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, Messing J, Kim HJ, Soriano A, Auburger G et al (2017) Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544:367–371. https://doi.org/10.1038/nature22038 View ArticlePubMedPubMed CentralGoogle Scholar
- Begcevic I, Kosanam H, Martinez-Morillo E, Dimitromanolakis A, Diamandis P, Kuzmanov U, Hazrati LN, Diamandis EP (2013) Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer's disease and age-matched control brains. Clin Proteomics 10:5. https://doi.org/10.1186/1559-0275-10-5 View ArticlePubMedPubMed CentralGoogle Scholar
- Combs B, Kanaan NM (2017) Exposure of the amino terminus of tau is a pathological event in multiple Tauopathies. Am J Pathol 187:1222–1229. https://doi.org/10.1016/j.ajpath.2017.01.019 View ArticlePubMedPubMed CentralGoogle Scholar
- Couthouis J, Hart MP, Erion R, King OD, Diaz Z, Nakaya T, Ibrahim F, Kim HJ, Mojsilovic-Petrovic J, Panossian S et al (2012) Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum Mol Genet 21:2899–2911. https://doi.org/10.1093/hmg/dds116 View ArticlePubMedPubMed CentralGoogle Scholar
- Couthouis J, Hart MP, Shorter J, DeJesus-Hernandez M, Erion R, Oristano R, Liu AX, Ramos D, Jethava N, Hosangadi D et al (2011) A yeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci U S A 108:20881–20890View ArticlePubMedPubMed CentralGoogle Scholar
- Fujita K, Ito H, Nakano S, Kinoshita Y, Wate R, Kusaka H (2008) Immunohistochemical identification of messenger RNA-related proteins in basophilic inclusions of adult-onset atypical motor neuron disease. Acta Neuropathol 116:439–445. https://doi.org/10.1007/s00401-008-0415-x View ArticlePubMedGoogle Scholar
- Gu J, Chen F, Iqbal K, Gong CX, Wang X, Liu F (2017) Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: implications for the pathogenesis of tauopathies. J Biol Chem 292:10600–10612. https://doi.org/10.1074/jbc.M117.783498 View ArticlePubMedPubMed CentralGoogle Scholar
- Gunawardana CG, Mehrabian M, Wang X, Mueller I, Lubambo IB, Jonkman JE, Wang H, Schmitt-Ulms G (2015) The human tau Interactome: binding to the Ribonucleoproteome, and impaired binding of the proline-to-leucine mutant at position 301 (P301L) to chaperones and the proteasome. Mol Cell Proteomics 14:3000–3014. https://doi.org/10.1074/mcp.M115.050724 View ArticlePubMedPubMed CentralGoogle Scholar
- Hackman P, Sarparanta J, Lehtinen S, Vihola A, Evila A, Jonson PH, Luque H, Kere J, Screen M, Chinnery PF et al (2013) Welander distal myopathy is caused by a mutation in the RNA-binding protein TIA1. Ann NeurolGoogle Scholar
- Hales CM, Dammer EB, Diner I, Yi H, Seyfried NT, Gearing M, Glass JD, Montine TJ, Levey AI, Lah JJ (2014) Aggregates of small nuclear ribonucleic acids (snRNAs) in Alzheimer's disease. Brain Pathol 24:344–351. https://doi.org/10.1111/bpa.12133 View ArticlePubMedPubMed CentralGoogle Scholar
- Hales CM, Seyfried NT, Dammer EB, Duong D, Yi H, Gearing M, Troncoso JC, Mufson EJ, Thambisetty M, Levey AI et al (2014) U1 small nuclear ribonucleoproteins (snRNPs) aggregate in Alzheimer's disease due to autosomal dominant genetic mutations and trisomy 21. Mol Neurodegener 9:15. https://doi.org/10.1186/1750-1326-9-15 View ArticlePubMedPubMed CentralGoogle Scholar
- Hernandez-Vega A, Braun M, Scharrel L, Jahnel M, Wegmann S, Hyman BT, Alberti S, Diez S, Hyman AA (2017) Local nucleation of microtubule bundles through tubulin concentration into a condensed tau phase. Cell Rep 20:2304–2312. https://doi.org/10.1016/j.celrep.2017.08.042 View ArticlePubMedPubMed CentralGoogle Scholar
- Hirsch-Reinshagen V, Pottier C, Nicholson AM, Baker M, Hsiung GR, Krieger C, Sengdy P, Boylan KB, Dickson DW, Mesulam M et al (2017) Clinical and neuropathological features of ALS/FTD with TIA1 mutations. Acta Neuropathol Commun 5:96. https://doi.org/10.1186/s40478-017-0493-x View ArticlePubMedPubMed CentralGoogle Scholar
- Hughes MP, Sawaya MR, Boyer DR, Goldschmidt L, Rodriguez JA, Cascio D, Chong L, Gonen T, Eisenberg DS (2018) Atomic structures of low-complexity protein segments reveal kinked beta sheets that assemble networks. Science 359:698–701. https://doi.org/10.1126/science.aan6398 View ArticlePubMedGoogle Scholar
- Ikezu T, Chen C, DeLeo AM, Zeldich E, Fallin MD, Kanaan NM, Lunetta KL, Abraham CR, Logue MW, Farrer LA (2018) Tau phosphorylation is impacted by rare AKAP9 mutations associated with Alzheimer disease in African Americans. J Neuroimmune Pharmacol. https://doi.org/10.1007/s11481-018-9781-x
- Ishigaki S, Fujioka Y, Okada Y, Riku Y, Udagawa T, Honda D, Yokoi S, Endo K, Ikenaka K, Takagi S et al (2017) Altered tau isoform ratio caused by loss of FUS and SFPQ function leads to FTLD-like phenotypes. Cell Rep 18:1118–1131. https://doi.org/10.1016/j.celrep.2017.01.013 View ArticlePubMedGoogle Scholar
- Kanaan NM, Pigino GF, Brady ST, Lazarov O, Binder LI, Morfini GA (2013) Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system. Exp Neurol 246:44–53. https://doi.org/10.1016/j.expneurol.2012.06.003 View ArticlePubMedGoogle Scholar
- Kim HJ, Raphael AR, LaDow ES, McGurk L, Weber RA, Trojanowski JQ, Lee VM, Finkbeiner S, Gitler AD, Bonini NM (2014) Therapeutic modulation of eIF2alpha phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet 46:152–160. https://doi.org/10.1038/ng.2853 View ArticlePubMedGoogle Scholar
- Li P, Banjade S, Cheng HC, Kim S, Chen B, Guo L, Llaguno M, Hollingsworth JV, King DS, Banani SF et al (2012) Phase transitions in the assembly of multivalent signalling proteins. Nature 483:336–340. https://doi.org/10.1038/nature10879 View ArticlePubMedPubMed CentralGoogle Scholar
- Lin Y, Protter DS, Rosen MK, Parker R (2015) Formation and maturation of phase-separated liquid droplets by RNA-binding proteins. Mol Cell 60:208–219. https://doi.org/10.1016/j.molcel.2015.08.018 View ArticlePubMedPubMed CentralGoogle Scholar
- Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderweyde T, Citro A, Mehta T, Zaarur N, McKee A, Bowser R, Sherman M et al (2010) Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One 5:e13250. https://doi.org/10.1371/journal.pone.0013250 View ArticlePubMedPubMed CentralGoogle Scholar
- Maziuk B, Ballance HI, Wolozin B (2017) Dysregulation of RNA binding protein aggregation in neurodegenerative disorders. Front Mol Neurosci 10:89. https://doi.org/10.3389/fnmol.2017.00089 View ArticlePubMedPubMed CentralGoogle Scholar
- Meier S, Bell M, Lyons DN, Ingram A, Chen J, Gensel JC, Zhu H, Nelson PT, Abisambra JF (2015) Identification of novel tau interactions with endoplasmic reticulum proteins in Alzheimer's disease brain. J Alzheimers Dis 48:687–702. https://doi.org/10.3233/JAD-150298 View ArticlePubMedPubMed CentralGoogle Scholar
- Meier S, Bell M, Lyons DN, Rodriguez-Rivera J, Ingram A, Fontaine SN, Mechas E, Chen J, Wolozin B, LeVine H 3rd et al (2016) Pathological tau promotes neuronal damage by impairing ribosomal function and decreasing protein synthesis. J Neurosci 36:1001–1007. https://doi.org/10.1523/JNEUROSCI.3029-15.2016 View ArticlePubMedPubMed CentralGoogle Scholar
- Molliex A, Temirov J, Lee J, Coughlin M, Kanagaraj AP, Kim HJ, Mittag T, Taylor JP (2015) Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell 163:123–133. https://doi.org/10.1016/j.cell.2015.09.015 View ArticlePubMedPubMed CentralGoogle Scholar
- Nott TJ, Petsalaki E, Farber P, Jervis D, Fussner E, Plochowietz A, Craggs TD, Bazett-Jones DP, Pawson T, Forman-Kay JD et al (2015) Phase transition of a disordered nuage protein generates environmentally responsive membraneless organelles. Mol Cell 57:936–947. https://doi.org/10.1016/j.molcel.2015.01.013 View ArticlePubMedPubMed CentralGoogle Scholar
- Panas MD, Ivanov P, Anderson P (2016) Mechanistic insights into mammalian stress granule dynamics. J Cell Biol 215:313–323. https://doi.org/10.1083/jcb.201609081 View ArticlePubMedPubMed CentralGoogle Scholar
- Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E et al (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:476–481View ArticlePubMedPubMed CentralGoogle Scholar
- Shin Y, Brangwynne CP (2017) Liquid phase condensation in cell physiology and disease. Science 357. https://doi.org/10.1126/science.aaf4382
- Shukla S, Parker R (2016) Hypo- and hyper-assembly diseases of RNA-protein complexes. Trends Mol Med 22:615–628. https://doi.org/10.1016/j.molmed.2016.05.005 View ArticlePubMedPubMed CentralGoogle Scholar
- Silva JM, Rodrigues S, Sampaio-Marques B, Gomes P, Neves-Carvalho A, Dioli C, Soares-Cunha C, Takashima A, Ludovico P, Wolozin B et al (2018) Dysregulation of autophagy and stress-granule related proteins in stress-driven tau pathology. Cell Death Differ (in press)Google Scholar
- Sun Y, Ip P, Chakrabartty A (2017) Simple elimination of background fluorescence in formalin-fixed human brain tissue for immunofluorescence microscopy. J Vis Exp: Doi. https://doi.org/10.3791/56188
- Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, Shorter J, Gitler AD (2011) Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol 9:e1000614. https://doi.org/10.1371/journal.pbio.1000614 View ArticlePubMedPubMed CentralGoogle Scholar
- Thompson AD, Scaglione KM, Prensner J, Gillies AT, Chinnaiyan A, Paulson HL, Jinwal UK, Dickey CA, Gestwicki JE (2012) Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation. ACS Chem Biol 7:1677–1686View ArticlePubMedPubMed CentralGoogle Scholar
- Vanderweyde T, Apicco DJ, Youmans-Kidder K, Ash PE, Cook C, Lummertz da Rocha E, Jansen-West K, Frame AA, Citro A, Leszyk JD et al (2016) Interaction of tau with the RNA-binding protein TIA1 regulates tau pathophysiology and toxicity. Cell Rep 15:1–12. https://doi.org/10.1016/j.celrep.2016.04.045 View ArticleGoogle Scholar
- Vanderweyde T, Yu H, Varnum M, Liu-Yesucevitz L, Citro A, Ikezu T, Duff K, Wolozin B (2012) Contrasting pathology of stress granule proteins TIA-1 and G3BP in Tauopathies. J Neurosci 32:8270–8283View ArticlePubMedPubMed CentralGoogle Scholar
- Wegmann S, Eftekharzadeh B, Tepper K, Zoltowska KM, Bennett RE, Dujardin S, Laskowski PR, MacKenzie D, Kamath T, Commins C et al (2018) Tau protein liquid-liquid phase separation can initiate tau aggregation. EMBO J. https://doi.org/10.15252/embj.201798049
- White MA, Kim E, Duffy A, Adalbert R, Phillips BU, Peters OM, Stephenson J, Yang S, Massenzio F, Lin Z et al (2018) TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. https://doi.org/10.1038/s41593-018-0113-5
- Zempel H, Mandelkow E (2014) Lost after translation: missorting of tau protein and consequences for Alzheimer disease. Trends Neurosci 37:721–732. https://doi.org/10.1016/j.tins.2014.08.004 View ArticlePubMedGoogle Scholar
- Zhang X, Lin Y, Eschmann NA, Zhou H, Rauch JN, Hernandez I, Guzman E, Kosik KS, Han S (2017) RNA stores tau reversibly in complex coacervates. PLoS Biol 15:e2002183. https://doi.org/10.1371/journal.pbio.2002183 View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang Y, Chen X, Zhao Y, Ponnusamy M, Liu Y (2017) The role of ubiquitin proteasomal system and autophagy-lysosome pathway in Alzheimer's disease. Rev Neurosci 28:861–868. https://doi.org/10.1515/revneuro-2017-0013 PubMedGoogle Scholar